Galanis E, Anderson SK, Twohy EL, et al. - Because bevacizumab-induced glioma invasion was effectively blocked by dasatinib (Src family kinase inhibitor) in preclinical models, researchers examined if bevacizumab efficacy in patients with recurrent glioblastoma (GBM) could be increased by combining bevacizumab with dasatinib. A phase 2 trial was performed, following the completion of the phase 1 component, where patients with recurrent GBM were randomized 2:1 to receive 100 mg of oral dasatinib twice daily (arm A) or placebo (arm B) on days 1 to 14 of each 14-day cycle combined with 10 mg/kg of intravenous bevacizumab on day 1 of each 14-day cycle. Six-month progression-free survival (PFS6) was assessed as primary endpoint. Among 121 evaluable patients, in arm A vs arm B, a numerically, but not statistically, higher PFS6 rate was observed, nor was there a significant difference in overall survival. No significant improvement in outcomes was achieved with the combination of bevacizumab with dasatinib vs bevacizumab alone in patients with recurrent GBM, despite upregulation of Src signaling in GBM patients.